GENEDX HOLDINGS (WGS)
(Delayed Data from NSDQ)
$26.19 USD
-1.06 (-3.89%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $26.14 -0.05 (-0.19%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.19 USD
-1.06 (-3.89%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $26.14 -0.05 (-0.19%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Zacks News
GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 51.47% and 25.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Take the Zacks Approach to Beat the Market: Virtu, Coinbase, General Mills in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
GENEDX HOLDINGS (WGS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Bears are Losing Control Over GeneDx Holdings Corp. (WGS), Here's Why It's a 'Buy' Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for GeneDx Holdings Corp. (WGS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
PacBio (PACB) Inks Research Collaboration for Genome Sequencing
by Zacks Equity Research
PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Revio system to explore novel variants.
Brookdale (BKD) May 2023 Occupancy Rises: Better Days Ahead?
by Zacks Equity Research
Brookdale (BKD) has witnessed 19 straight months of year-over-year increases in weighted average occupancy level.
Humana (HUM) Arm Reaches 250 Senior Primary Care Facilities
by Zacks Equity Research
Humana's (HUM) CenterWell business focuses on providing a better healthcare experience through clubbing primary care, home health and pharmacy services.
Should You Retain Acadia Healthcare (ACHC) in Your Portfolio?
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is likely to receive support from growth in specialty treatment and acute inpatient psychiatric facilities.
Encompass Health (EHC) to Build New Hospital in Concordville
by Zacks Equity Research
The new inpatient rehabilitation unit is likely to be the 10th hospital of Encompass Health (EHC) in Pennsylvania.
HCA Healthcare (HCA) to Acquire 41 Urgent Care Centers in Texas
by Zacks Equity Research
HCA Healthcare (HCA) expects the acquisition of urgent care centers from FastMed to close by this summer.
Here's Why Hold Strategy is Apt for Centene (CNC) Stock Now
by Zacks Equity Research
Centene's (CNC) health benefit ratio is estimated at 87.1-87.7% for 2023, signaling better operating efficiency.
Down -27.82% in 4 Weeks, Here's Why You Should You Buy the Dip in GeneDx Holdings Corp. (WGS)
by Zacks Equity Research
GeneDx Holdings Corp. (WGS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Elevance (ELV) to Divest Life & Disability Business to StanCorp
by Zacks Equity Research
With the sale of the life and disability business, Elevance Health (ELV) is focusing on growing its more profitable operations.
Similar Genomics Systems (OMIC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Similar Genomics Systems (OMIC) delivered earnings and revenue surprises of 21.62% and 27.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Agilon Health (AGL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of -75% and 3.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?